Abbott Laboratories

New York Stock Exchange
Back to all articles
Slightly Bullish +25

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

AI-generated analysis

🏥 Abbott Laboratories secured FDA De Novo authorization for the Libre Duo, becoming the first wearable cleared to continuously monitor glucose and detect ketones.

📉 The stock has fallen 11% year-over-year despite a recent 9.2% rally, currently trading at $114.10 with an analyst price target of $120.20.

💰 Q2 CGM sales reached $2.188 billion, representing a 9.5% comparable growth rate as the company defends against deceleration narratives.

🤝 Planned integrations with insulin pumps from partners like Tandem and Insulet are identified as the commercial hinge for Libre Duo's adoption.

👥 The device targets an existing ecosystem of over 8 million users, with a planned U.S. launch later in 2026 for patients ages 2 and older.

📈 CEO Robert Ford highlighted that reimbursement expansion could drastically accelerate growth, potentially reaching around 10 million Medicare beneficiaries.

⚠️ Analysts caution that the regulatory win is insufficient on its own to warrant a stock re-rating until pump partners ship integrated systems.

🔍 The FDA authorization confirms Abbott's timeline for U.S. discussions which were previously described as being in very advanced final stages.

Bullish Signals
  • Abbott Laboratories achieved a regulatory first with the FDA De Novo authorization for the Libre Duo, becoming the only company with a wearable cleared to continuously monitor both glucose and ketones.
  • The company reported strong Q2 CGM sales of $2.188 billion, growing 9.5% on a comparable basis, demonstrating resilience in its core diabetes business.
  • Abbott raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60, signaling confidence in future earnings performance.
  • The Libre Duo targets an established ecosystem of over 8 million users, providing a substantial existing customer base for the new device.
Risk Factors
  • Abbott's stock has declined 11% over the past year and 7.25% year-to-date, indicating market skepticism regarding its current valuation despite recent regulatory wins.
  • Planned integrations with insulin pumps from key partners like Tandem and Insulet are not yet live in the U.S., limiting the immediate workflow impact of the Libre Duo.
  • Analysts view the FDA authorization as insufficient on its own to warrant a stock re-rating until reimbursement announcements and pump partner shipments occur.
Full Analysis
Abbott Laboratories received FDA De Novo authorization for the Libre Duo, becoming the first company with a wearable device capable of continuously monitoring both glucose and ketone levels. This regulatory milestone targets an existing ecosystem of over 8 million users and aims to detect rising ketones that can precede diabetic ketoacidosis within hours, offering a genuine clinical distinction in diabetes care. Despite this breakthrough, Abbott's stock has declined 11% over the past year, trading at a forward P/E of 21x against an analyst target of $120.20. The company raised its full-year adjusted EPS guidance to between $5.45 and $5.60, while Q2 continuous glucose monitoring (CGM) sales reached $2.188 billion, growing 9.5% on a comparable basis. CEO Robert Ford emphasized that reimbursement expansion is critical for accelerating growth. The commercial success of the Libre Duo hinges on future integrations with insulin pumps from major partners like Tandem and Insulet, which are not yet live in the U.S. Additionally, potential coverage for around 10 million Medicare beneficiaries could significantly impact adoption. Analysts view the authorization as meaningful but insufficient alone to warrant a stock re-rating until pump partners ship integrated systems and CMS moves on broader Type 2 coverage.